Table 2.

Patient tumor specimens that were unsuccessful in generating patient-derived xenograft models

	Tumor ID	TNM	Diagnosis	Treatment prior to tissue collection	Current status	Platform used to detect mutations	BRAF	TP53	Other mutations
1	P178	T4bN1bM0	ATC	None	Deceased	IHC	WT	Yes	None
2	P184	T4bN1bM1	ATC	None	Deceased	50-Gene somatic mutation analysis	WT	WT	None
3	P215	T4bN1bM1	ATC	None	Deceased	IHC and solid tumor genomics assay	WT	R248W	DNMT3A
4	P220LN	T4aN1aM1	ATC with extensive squamous differentiation, LN	Dabrafenib, trametinib	Deceased	IHC and solid tumor genomics assay	V600E	WT	PIK3CA
5	P221	T3NxM0	ATC arising from a follicular neoplasm	None	Deceased	IHC	WT	WT	None
6	P225	T4aN1bM0	PTC with anaplastic (undifferentiated) component (~ 10%)	None	Alive	IHC and solid tumor genomics assay	WT	R280K	CDH1 CDKN2A NF1 PIK3CA
7	P239	T4N1bM0	ATC and PTC	Abraxane, dabrafenib, trametinib	Deceased	IHC and solid tumor genomics assay	V600E	Q331a	None
8	P244	T4aN1bM0	ATC, squamous type	None	Alive	IHC and solid tumor genomics assay	WT	E56a	TERT RB1
9	P245	T4aN1bM0	ATC (40%) with PDTC	None	Deceased	Solid tumor genomics assay	WT	WT	None
10	P258	T4bN1bM0	ATC	Dabrafenib, trametinib	Deceased	IHC and solid tumor genomics assay	V600E	WT	NF2 TERT
11	P264	T4bN1bM1	ATC	Radiation	Deceased	IHC and solid tumor genomics assay	D594N	WT	NRAS TERT
12	P265	T4bN1bM1	ATC	Lenvatinib, dabrafenib, trametinib	Alive	IHC and solid tumor genomics assay	V600E	WT	PIK3CA TERT
13	P267	T4aN0M0	ATC	None	Alive	Solid tumor genomics assay	WT	R273C	ATM NF1 NOTCH3 RET

Abbreviations: ATC, anaplastic thyroid cancer; ID, identification; IHC, immunohistochemistry; LN, lymph node; PDTC, poorly differentiated thyroid cancer; TERT, TERT promoter; WT, wild-type.

^a Nonsense mutation.